Balanced news tone
News Sentiment
OABI sentiment intelligence
OmniAb Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-5.4% over one week, +0.9% over four weeks, trend active, and below fair value.
OmniAb to Report Second Quarter 2026 Financial Results on August 6
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
OmniAb shareholders elect directors and ratify auditor at annual meeting By Investing.com
OmniAb, Inc. (NASDAQ:OABI) held its 2026 Annual Meeting where shareholders elected Jennifer Cochran, Ph.D., and Matthew W. Foehr as Class I directors for three-year terms. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fi
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 19 Jun 2026 02:40
- Source
- Investing.com Nigeria
OmniAb (OABI) director Bertozzi exercises RSUs and receives new option, RSU grants
OmniAb director Carolyn R. Bertozzi exercised 20,000 Restricted Stock Units (RSUs) into common stock, increasing her direct holdings to 113,308 shares. She also received grants of 40,000 stock options at an exercise price of $2.03 and 20,000 new RSUs. Both the new RSUs and stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 23:40
- Source
- Stock Titan
OmniAb (OABI) 2026 annual meeting elects directors and ratifies auditor
OmniAb, Inc. (OABI) held its 2026 Annual Meeting of Shareholders on June 17, 2026. During the meeting, shareholders elected Jennifer Cochran, Ph.D. and Matthew W. Foehr as Class I directors for three-year terms. Additionally, Ernst & Young LLP was ratified as the independent regi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 23:10
- Source
- Stock Titan
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
OmniAb, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-05-11
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Seeking Alpha
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
OmniAb, Inc. Q1 2026 Earnings Call Summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 12:30
- Source
- Moby
OmniAb Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 11:07
- Source
- MarketBeat
OmniAb (OABI) Q1 2026 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- The Motley Fool
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- BioSpace
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Insider Buyers At OmniAb Likely Disappointed With 13% Slide
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- simplywall.st
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Bullish OmniAb Insiders Loaded Up On US$1.28m Of Stock
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- Market source
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Truist reiterates OmniAb stock Buy rating on biotech recovery
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 27 Mar 2026 07:00
- Source
- Investing.com
OmniAb (OABI) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:41
- Source
- Stock Titan
Should I buy OmniAb, Inc. (OABI)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Nov 2022 15:42
- Source
- Zacks Investment Research
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 23 Mar 2022 07:00
- Source
- Business Wire